secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000059478-23-000282
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q3 revenue up 37% to $9.5B; reported EPS loss $0.06 on $3.29 IPR&D charges, non-GAAP EPS $0.10
--------------------------------------------------------------------------------

- Revenue $9,498.6M (+37% YoY) driven by Mounjaro, Verzenio, and $1.42B from olanzapine rights sale.
- Reported net loss of $57.4M ($0.06 loss per share); non-GAAP net income $94.8M ($0.10 EPS).
- Acquired IPR&D charges of $3.29/share and olanzapine gain of $1.22/share impacted EPS.
- 2023 reported EPS guidance lowered to $5.95-$6.15; non-GAAP EPS to $6.50-$6.70.
- Completed acquisitions of DICE, Versanis, Emergence, Sigilon; agreed to buy POINT Biopharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000282/0000059478-23-000282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000282/lly-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000059478-23-000282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer